More details have emerged in the latest Anderson Silva doping case.
Prior to his scheduled fight last November at UFC Fight Night 122 with Kelvin Gastelum in Shanghai, the 42-year-old Silva was informed on Nov. 10 that he had failed a U.S. Anti-Doping Agency test and faced suspension. Now, we have an idea of what he failed for.
According to a Thursday report by Brazil’s Combate.com, Silva failed his drug test administered on Oct. 26 of last year for methyltestosterone and an unnamed diuretic. He faces a potential four-year ban from USADA, but under the “aggravated circumstance” clause the USADA is able to pursue, it’s possible that all-time greatest middleweight could face eight years on the shelf.
At UFC 183 in January 2015, Silva won a unanimous decision over Nick Dia, but ultimate tested positive for two anabolic steroids, Drostanolone and Androstane, as well as two benzodiazepines, Oxazepam and Temazepam. As USADA was not presiding over the Ultimate Fighting Championship’s drug testing at this point, according to reports, Silva’s team is seeking to have his positive drug test pursuant to UFC 183 thrown out when considering his suspension. Silva's tests were administered by the Nevada Athletic Commission, who was suspended one year and fined $165,000 dollars after initially facing five-year suspension.
The Combate report further alleges that Silva plans on retiring if he receives any more than two-year ban from competition.
Silva’s last action in the Octagon came at UFC 208 in February of last year when he won a contentious unanimous decision over Derek Brunson in Brooklyn.